January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
11 citations
,
March 2024 in “Current Issues in Molecular Biology” Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
March 2024 in “Journal of the American Academy of Dermatology” 31 citations
,
January 1993 in “Skin Pharmacology and Physiology” Potassium channel openers can boost hair growth by stimulating DNA in hair follicles.
February 2012 in “Hospital Pharmacy”
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
43 citations
,
May 1978 in “JAMA” Minoxidil controls blood pressure but may cause kidney damage and needs diuretics to prevent swelling.
45 citations
,
January 1981 in “Annals of Internal Medicine” Minoxidil controls blood pressure effectively, but may cause side effects like hypertrichosis.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
25 citations
,
July 2015 in “Colloids and Surfaces B: Biointerfaces” Iontophoresis improves minoxidil delivery to hair follicles for hair loss treatment.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
October 2025 in “Frontiers in Endocrinology” Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
October 2025 in “Journal of the Endocrine Society” Methimazole can cause severe low platelet count in Graves' disease patients, so monitoring and alternative treatments are important.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
1 citations
,
October 2002 in “The Journal of Urology”
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
6 citations
,
January 1977 in “PubMed” Minoxidil effectively lowers severe high blood pressure long-term but isn't for routine use.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
11 citations
,
September 2014 in “International Journal of Molecular Sciences” Mycophenolate helps reverse hair loss effects caused by IFN-γ by activating a key hair growth pathway.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”